The mean percentage of FGFR2-positive expression was 12.5% (SD = 34.2%) in normal histology, 76.5% (SD = 43.7%) in malignant tumors, 52.2% (SD = 50%) in precancerous lesions, and 50.4% (SD = 50.2%) in benign tumors. This evidence concerns the gene FGFR2 and cancer.